[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100291989":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":31,"locations":36,"responsibleParty":50,"collaborators":21,"id":53,"slug":21,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":21,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":21,"enrollmentInfo":60,"targetDuration":21,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":38,"whyStopped":21,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Louisville","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Arm","EXPERIMENTAL","All patients undergoing irreversible electroporation will be treated with nivolumab",[13,14],"Drug: Nivolumab","Procedure: Irreversible Electroporation",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Nivolumab","Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"PROCEDURE","Irreversible Electroporation","Non-thermal ablation of tumor",[9],[28],{"name":29,"affiliation":5,"role":30},"Robert Martin, MD, PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","502-629-3355","robert.martin@louisville.edu",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":21},"RECRUITING","Louisville","Kentucky","40202","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-85.75941,38.25424,{"lat":48,"lon":47},{"type":30,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Robert C. Martin","Principal Investigator","100291989",false,"NCT03080974","Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* ≥ 18 years if age\n* Diagnosed with stage III pancreatic cancer\n* Tumor is measurable\n* Glomerular Filtration Rate \\> 60 m\u002FL\u002Fmin\u002F1.73 m(2)\n* Willing and able to comply with the protocol requirements\n* Able to comprehend and have signed the informed consent to participate\n\nExclusion Criteria:\n\n* Participating in another clinical trial for the treatment of cancer at time of screening\n* Are pregnant or currently breast feeding\n* Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure\n* Have non-removable implants with metal parts within 1 cm of the target lesion\n* Had a myocardial infarction within 3 months prior to enrollment","ALL","18 Years",{"count":61,"type":62},10,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.",[68],"Pancreatic Adenocarcinoma",[70,18],"irreversible electroporation","2025-10-27",{"date":73,"type":74},"2025-10-29","ACTUAL",{"date":76,"type":74},"2017-08-14",{"date":78,"type":62},"2029-04-01",{"name":5,"class":6},1]